Servier regularly invests more than 25% of its annual turnover in research and development, which is significantly higher than the industry average of 17%. More than 2,600 of a total 20,000 employees across the world are dedicated to Research and Development.
Servier’s Research and Development pipeline is extremely healthy, having the potential to submit several true innovations for licence during the next 10 years.
As a priority, Servier invests in therapeutic areas where there is a medical need. From a product portfolio focused on Cardiovascular disease, Diabetes and Osteoporosis, Servier plans to develop new and existing products by 2014 for Type 2 diabetes, hypertension, heart failure, prevention of cardiovascular events, depression and neurodegenerative diseases, oncology and osteoarthritis.
We carry out extensive clinical research in the UK through the International Centre for Therapeutic Research.
© 2007 LES LABORATOIRES SERVIER, an incorporated company of SERVIER. All Rights Reserved - Terms of Use
SERVIER does not sell its products over the Internet - More information
Last Updated 15/06/2011 10:41:01
Best viewed in Internet Explorer 6.0 or later, at 1024x768 resolution.